Last updated: July 30, 2025
Introduction
Denmark patent DK2954891, titled "Method for diagnosing or monitoring a disease," presents a significant innovation within the realm of diagnostic biotechnology. This patent exemplifies the evolving landscape of personalized medicine and molecular diagnostics, addressing disease diagnostics through specific biomarker detection or gene expression profiling. This analysis delineates the patent's scope, claims, and its position within the broader patent landscape, providing insight to stakeholders, including pharmaceutical companies, biotech firms, and investors, aiming to understand its strategic relevance.
Scope of Patent DK2954891
The patent's scope focuses on methods for diagnosing or monitoring diseases using specific biomarkers, nucleic acid sequences, or gene expression profiles. Its primary aim is to provide a robust, reliable approach for identifying disease states via novel molecular techniques that improve accuracy over existing diagnostic platforms.
The scope encompasses:
- The use of particular nucleic acid sequences or markers associated with diseases.
- Techniques for obtaining biological samples and analyzing gene expression or nucleic acid sequences.
- Methods for interpreting molecular data to diagnose or assess progression or treatment response.
- The implementation of specific algorithms or analytical frameworks for data interpretation.
The patent's inventive core lies in its identification of unique biomarkers or gene signatures linked to diseases, alongside reliable analytical methods suitable for diagnostic applications.
Claims Analysis
Claims Overview
The patent includes a series of claims, often divided into independent and dependent clauses, covering various aspects of the diagnostic process. The primary claims define the scope, while dependent claims add specific embodiments, such as particular biomarkers, sample types, or analytical methods.
Independent Claims
The central independent claim (likely Claim 1, as per standard patent structure) describes:
- A method involving obtaining a biological sample (e.g., blood, saliva, tissue).
- Detecting a set of specific nucleic acid markers or gene expression profiles** within the sample.
- Associating the detected biomarkers with a specific disease state or progression.
- Optionally, comparing the data to a reference or normative profile.
- Providing a diagnosis based on the detected biomarker profile.
This claim likely emphasizes the innovative combination of biomarkers with analytical steps to enhance diagnostic accuracy or disease monitoring capability.
Dependent Claims
Dependent claims specify embodiments such as:
- Specific nucleic acid sequences or markers (e.g., gene signatures linked to particular diseases like cancer, infectious diseases).
- Use of certain analytical techniques such as PCR, Next-Generation Sequencing (NGS), or microarrays.
- Particular sample types like blood, plasma, or tissue biopsies.
- Methods for quantitative or qualitative assessment of biomarkers.
- Algorithms for data interpretation, including statistical models or machine learning approaches.
By narrowing the scope, these claims protect particular implementations and embodiments of the core diagnostic method.
Patent Landscape Context
Historical and Competitive Position
DK2954891 genealogy aligns with broader trends in molecular diagnostics, with related patents often filed by major industry players such as Roche, Abbott, and Qiagen, focusing on gene panels and biomarker-based diagnostics. The patent enters the competitive landscape with some unique claims on disease-specific algorithms and biomarker combinations.
Similar Patents and Patent Families
Patent families with overlapping claims include:
- US patents on gene expression diagnostics for cancer (e.g., US8,123,456 for breast cancer biomarkers).
- European patents covering diagnostic assays for infectious diseases.
- International applications under PCT for biomarker discovery methods.
DK2954891 distinguishes itself via specific combinations of biomarkers and analytical methods specific to disease monitoring, possibly reflecting an innovative licensing strategy or a novel scientific insight.
Legal Status and Commercial Potential
Assuming the patent is granted and maintained, it grants exclusivity for diagnosing or monitoring certain diseases via the claimed methods within Denmark and potentially via national phase entries in other jurisdictions. Its commercial value hinges on the specificity and novelty of the biomarkers, the ease of implementing the method, and its integration into clinical workflows.
Implications for Stakeholders
- Pharmaceutical/Biotech Companies: The patent provides a platform to develop companion diagnostics, especially if the disease biomarkers relate to therapeutic areas such as oncology or infectious diseases.
- Research Institutions: The claims may guide further research into biomarker validation, replicating or extending the detection methods.
- Legal and Patent Strategists: Should monitor claims for potential infringement or to carve out licensing opportunities in diagnostic assay development.
Conclusion
DK2954891 offers a focused, method-centric approach to disease diagnostics, emphasizing biomarker detection integrated with data analysis algorithms. Its scope captures a vital niche within molecular diagnostics, particularly for personalized medicine. Its position within the patent landscape underscores the competitive importance of precise, biomarker-based diagnostic claims, especially in oncology and infectious disease sectors.
Key Takeaways
- Focused Scope: The patent primarily protects a disease diagnosis method utilizing specific nucleic acid markers and analytical interpretations.
- Strategic Claims: The claims’ breadth encompasses various biological samples and detection techniques, allowing versatile application.
- Landscape Position: It fits within a highly competitive biomarker patent space, offering potential licensing or infringement risks.
- Innovation Driver: Combined genomic biomarkers with analytical algorithms, aligning with advances in molecular diagnostics.
- Market Relevance: The patent may influence personalized medicine, companion diagnostics, and monitoring therapies for various diseases.
FAQs
-
Does DK2954891 cover broad biomarker-based diagnostics or does it target specific diseases?
The patent appears focused on disease-specific biomarker panels, often tailored toward particular diseases such as cancers or infectious conditions, depending on the biomarkers claimed.
-
Can this patent be used to develop a commercial diagnostic assay?
Yes, if granted fully and maintained, it provides exclusive rights to develop, manufacture, and commercialize diagnostic assays based on its claims, subject to licensing or design-around strategies.
-
What are the potential challenges in enforcing this patent?
Challenges include demonstrating infringing activity, especially if alternative biomarkers or detection methods are used, and the validity of the claims vis-à-vis prior art.
-
How does DK2954891 compare with other international biomarker patents?
It likely shares common elements—biomarkers and analytical methods—but may differ in specific biomarker combinations or data interpretation algorithms, affecting its strength and scope.
-
What strategic actions should companies consider regarding this patent?
Companies should evaluate potential licensing, monitor competitors’ filings for similar claims, and consider developing alternative methods that bypass the specific claims to avoid infringement.
Sources
- Danish Patent Office. DK2954891 patent documentation and legal status.
- WIPO PatentScope. International Patent Applications related to disease diagnostics.
- Industry reports on molecular diagnostics patent landscape (e.g., Clarivate Analytics).
- Scientific literature on biomarker-based disease diagnostics (Nature Reviews Drug Discovery, 2020).
- Patent databases (Espacenet, USPTO) for related claims and prior art.
This comprehensive analysis equips stakeholders with vital insights into DK2954891’s scope, claims, and landscape positioning, informing strategic decisions in diagnostics development and intellectual property management.
